This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
by Zacks Equity Research
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
GKOSPositive Net Change WSTPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?
by Indrajit Bandyopadhyay
CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.
CAHNegative Net Change MCKPositive Net Change
medical medical-devices
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
by Zacks Equity Research
BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.
BAXPositive Net Change ISRGPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
by Zacks Equity Research
The Cooper Companies opens a global innovation hub in England and unveils six contact lens programs to support sustainable long-term growth.
COOPositive Net Change ISRGPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
Illumina Stock Surges 94.9% YTD: What's Behind the Rally?
by Zacks Equity Research
ILMN's 94.9% YTD rally reflects strong sequencing growth, clinical adoption and a raised 2026 outlook despite China headwinds.
ILMNPositive Net Change TFXPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
by Nalak Das
AI adoption is reshaping medical devices, with ISRG, TEM and TMO leveraging AI to advance precision medicine and drug development.
ISRGPositive Net Change TMOPositive Net Change TEMPositive Net Change
medical-devices
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing
by Zacks Equity Research
VEEV launches Falcon Router to automate biopharma case routing, deepening AI integration across regulated life sciences workflows.
VEEVPositive Net Change WSTPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
by Zacks Equity Research
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.
NTRAPositive Net Change ISRGPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
by Zacks Equity Research
Inspire Medical is navigating a major product transition as clinical evidence, patient access efforts and reimbursement progress support growth prospects.
INSPPositive Net Change ISRGPositive Net Change GMEDPositive Net Change VCYTPositive Net Change
medical medical-devices
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
by Indrajit Bandyopadhyay
ISRG's rapid procedure growth, expanding robotics ecosystem and recurring revenues highlight its growth path amid MedTech shifts.
SYKPositive Net Change ISRGPositive Net Change
medical medical-devices